Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds JP Morgan Downgrades Offerpad Solutions to Neutral

JP Morgan Downgrades Offerpad Solutions to Neutral

JP Morgan analyst Dae Lee downgrades Offerpad Solutions (NYSE:OPAD) from Overweight to Neutral.

byBenzinga Newsdesk

March 8, 2023

1 minute read

JP Morgan analyst Dae Lee downgrades Offerpad Solutions (NYSE:OPAD) from Overweight to Neutral.

Analyst Ratings

A Closer Look at 10 Analyst Recommendations For Guess

By Benzinga Insights

April 8, 10:00 AM

Guess (NYSE:GES) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish…

GES

Is Your Botox Real Or Fake? Counterfeit Boxes Circulate For Widely Used Antiwrinkle Treatment, CDC And FDA Investigate Harmful Reactions

By Vandana Singh

April 17, 2:42 PM

Be cautious of counterfeit Botox for cosmetic use. FDA warns of adverse reactions in multiple states. Symptoms include vision issues, difficulty breathing, and weakness. Ensure authenticity before use.

ABBV

Barclays Initiates Coverage On BYD with Overweight Rating, Announces Price Target of $40

By Benzinga Newsdesk

September 13, 1:19 PM

Barclays analyst Jiong Shao initiates coverage on BYD (OTC:BYDDY) with a Overweight rating and announces Price Target of $40.

BYDDY

Citigroup Initiates Coverage On Redfin with Neutral Rating, Announces Price Target of $5

By Benzinga Newsdesk

December 13, 10:06 AM

Citigroup analyst Ygal Arounian initiates coverage on Redfin (NASDAQ:RDFN) with a Neutral rating and announces Price Target of $5.

RDFN

JP Morgan Downgrades Offerpad Solutions to Neutral

Related Posts

A Closer Look at 10 Analyst Recommendations For Guess

Is Your Botox Real Or Fake? Counterfeit Boxes Circulate For Widely Used Antiwrinkle Treatment, CDC And FDA Investigate Harmful Reactions

Barclays Initiates Coverage On BYD with Overweight Rating, Announces Price Target of $40

Citigroup Initiates Coverage On Redfin with Neutral Rating, Announces Price Target of $5